Biological activity of rhBMP-2 released from PLGA microspheres.
Human recombinant bone morphogenetic protein-2 (rhBMP-2) has been proven effective in stimulating the regeneration of bone in both skeletal and extraskeletal locations. Through encapsulation within, and release from, biodegradable poly(DL-lactic-co-glycolic acid) (PLGA) microspheres, a proven vehicle for sustained delivery of various proteins, the local concentrations of rhBMP-2 could be maintained at optimal levels to stimulate bone regeneration and remodeling at the site of healing in diverse clinical settings. Thus the purpose of this work was to investigate the encapsulation of rhBMP-2 in PLGA microspheres and its biologic activity upon release. Using in vitro tests in simulated body fluids, the effect of rhBMP-2 released from PLGA microspheres upon osteoblast cell cultures was found to be statistically similar to the effect produced by positive controls consisting of nonencapsulated aqueous rhBMP-2 in simulated body fluids. This clarifies an important step in skeletal tissue engineering strategies aimed at the use of encapsulated rhBMP-2 to stimulate bone regeneration and remodeling.
Department of Orthopedic Surgery, Mayo Clinic, Rochester, MN 55905, USA.
J B
JB
Oldham
L
L
Lu
X
X
Zhu
B D
BD
Porter
T E
TE
Hefferan
D R
DR
Larson
B L
BL
Currier
A G
AG
Mikos
M J
MJ
Yaszemski
D001672:Biocompatible Materials / Q000627:therapeutic use*; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins / Q000627:therapeutic use*; D001861:Bone Regeneration / Q000187:drug effects*; D016723:Bone Remodeling / Q000187:drug effects*; D002478:Cells, Cultured / Q000187:drug effects; D004337:Drug Carriers; D004353:Drug Evaluation, Preclinical; D005333:Fetus / Q000166:cytology; D006801:Humans; D019344:Lactic Acid / Q000627:therapeutic use*; D008863:Microspheres; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects*; D011100:Polyglycolic Acid / Q000627:therapeutic use*; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use*; D016212:Transforming Growth Factor beta
C525718:BMP2 protein, human; D001672:Biocompatible Materials; D055396:Bone Morphogenetic Protein 2; D019485:Bone Morphogenetic Proteins; D004337:Drug Carriers; D011108:Polymers; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid